Piper Jaffray Expands Healthcare Investment Banking, Appoints Head of West Coast Biotechnology
21 May 2013 - 12:54AM
Business Wire
Piper Jaffray (NYSE: PJC), a leading investment bank and asset
management firm, today announced that Andrew Gitkin joined the firm
as managing director and head of West Coast biotechnology
investment banking. Gitkin will be based in the firm’s San
Francisco office.
Gitkin brings nearly 20 years of healthcare financial services
experience to Piper Jaffray. He joins the firm from Moelis &
Co., where he was a senior investment banker in the life sciences
investment banking group. Gitkin’s prior experience includes
positions in investment banking, equity research and asset
management.
Gitkin has been recognized as part of the Institutional Investor
All-America team on numerous occasions for his prior research
coverage of biotechnology, healthcare services, medical supplies
and technology. He is a graduate of Emory University in
Atlanta.
“Our healthcare group is a market-leading platform across life
sciences, medical technology and healthcare services. Andrew brings
extensive experience advising emerging companies in the biotech
segment and advising consolidators with strategic direction. His
experience makes him the ideal candidate to lead and grow our West
Coast biotech efforts,” commented Bob DeSutter, head of Piper
Jaffray healthcare investment banking.
"Andrew is a great addition to our healthcare team,” added Chad
Abraham, global co-head of investment banking and capital markets
at Piper Jaffray. “Biotech is a strategic growth area for the firm
and Andrew’s hire highlights our continued focus on this franchise
to leverage our highly ranked advisory and equities business.”
Earlier this year, Piper Jaffray expanded its banking team by
hiring investment bankers, Peter Day and Jeff Ammerman who joined
the firm from Leerink Swan and Jefferies, respectively.
Piper Jaffray has a global healthcare investment banking and
capital markets team of 48. Since 2007, the team has represented
clients in 238 transactions with an aggregate value of $39 billion.
In addition, the firm’s 10 healthcare senior research analysts
cover a broad spectrum of sectors, including specialty
pharmaceuticals, biotechnology, medical technology, drug discovery,
medical diagnostics, life science tools and healthcare services,
including information technology and alternate site providers.
About Piper Jaffray
Piper Jaffray is a leading investment bank and asset management
firm serving clients in the U.S. and internationally. Our proven
advisory teams combine deep industry, product and sector expertise
with ready access to capital. Founded in 1895, the firm is
headquartered in Minneapolis and has offices across the United
States and in London and Zurich. www.piperjaffray.com
Since 1895. Member SIPC and NYSE. © 2013 Piper
Jaffray Companies, 800 Nicollet Mall, Suite 800, Minneapolis,
Minnesota 55402-7020
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Aug 2023 to Aug 2024